Interestingly, the N-terminal SH2 domain perturbed group is mutually exclusive with mutations affecting the interfaces of TP53 with DNA or co-regulators (p = 1.23e−3, q = 4.47e−2; Table S3a), with the latter being associated with poorer prognosis in breast carcinoma (a lower likelihood to completely remit: p = 6.17e−3, q = 8.63e−2; see Table S3a). This evidence concerns the gene TP53 and breast carcinoma.